Aclaris Therapeutics (ACRS) Accumulated Expenses (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Accumulated Expenses of $5.9 million for Q1 2026, down 31.22% year-over-year from $8.6 million in Q1 2025, and down 32.93% quarter-over-quarter from $8.8 million in Q4 2025.
Aclaris Therapeutics (ACRS) Accumulated Expenses (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $5.9 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 31.22% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (down 31.22% YoY), while the FY2025 annual figure was $8.8 million, up 76.56% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $5.9 million, down from $8.8 million in the prior quarter.
- The five-year high for Accumulated Expenses was $9.2 million in Q3 2022, with the low at $2.6 million in Q1 2024.
- The 5-year median for Accumulated Expenses is $5.0 million (2023), against an average of $4.9 million.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses sank 58.38% in 2022, then jumped 231.22% in 2025.
- Aclaris Therapeutics' Accumulated Expenses stood at $5.3 million in 2022, then slipped by 26.16% to $3.9 million in 2023, then grew by 27.34% to $5.0 million in 2024, then jumped by 76.56% to $8.8 million in 2025, then slumped by 32.93% to $5.9 million in 2026.
- Business Quant data shows ACRS's Accumulated Expenses at $5.9 million in Q1 2026, $8.8 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.96 Mn |
| Mar 31, 2026 | 5.90 Mn |
| Dec 31, 2025 | 8.79 Mn |
| Sep 30, 2025 | 3.76 Mn |
| Jun 30, 2025 | 2.74 Mn |
| Mar 31, 2025 | 8.57 Mn |
| Dec 31, 2024 | 4.98 Mn |
| Sep 30, 2024 | 2.60 Mn |
| Jun 30, 2024 | 5.76 Mn |
| Mar 31, 2024 | 2.59 Mn |
| Dec 31, 2023 | 3.91 Mn |
| Sep 30, 2023 | 4.97 Mn |
| Jun 30, 2023 | 3.91 Mn |
| Mar 31, 2023 | 2.63 Mn |
| Dec 31, 2022 | 5.30 Mn |
| Sep 30, 2022 | 9.15 Mn |
| Jun 30, 2022 | 2.89 Mn |
| Mar 31, 2022 | 5.69 Mn |
| Dec 31, 2021 | 4.39 Mn |
| Sep 30, 2021 | 2.85 Mn |